As the internalization of GRPR agonists after receptor binding may potentially result in a longer tumor retention period [1,32,33], radiolabeled [Thz14]Bombesin(7–14)-derived, GRPR-targeting ligands may be preferable to [Leu13ψThz14]Bombesin(7–14) derivatives, especially for radioligand therapy applications. The gene discussed is GRP; the disease is neoplasm.